Clinical Trials Browser

Phase 1/2 × Recruiting × osimertinib × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting

434 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT06618287 2026-03-17

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

416 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT04486833 2026-01-21

Acclaim-1

Phase 1/2 Recruiting

158 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07079475 2025-12-24

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Phase 1/2 Recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07206498 2025-11-28

WAYWIN103

Phase 1/2 Recruiting

48 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06306456 2024-07-08

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Phase 1/2 Recruiting

94 enrolled

Thoracic

Non-Small Cell Lung Cancer With EGFR Mutation

NCT06109558 2024-05-30

PROFILE

Phase 1/2 Recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Acclaim-1

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

WAYWIN103

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

PROFILE